

21 Esther Nasuuna

22 enasuuna@idi.co.ug

It is made available under a CC-BY-NC 4.0 International license. **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2024.09.02.24312932;](https://doi.org/10.1101/2024.09.02.24312932) this version posted September 3, 2024. The copyright holder for this preprint

68 estimates CKD prevalence at 9.1% (95% CI 8.5%-9.8%) with geographic variation (3). Studies in Sub-69 Saharan Africa (SSA) find prevalence ranging from 6%-48% depending on the population, the definitions 70 used, and the measurements taken (4-6). 71 Young people living with HIV (YPLHIV) are at higher risk of CKD than young people not living with 72 HIV (7). CKD risk is associated with high HIV viremia (>4000 copies per ml), severe 73 immunosuppression (CD4 cell count <200 cells/ml), infection with hepatitis C virus, diabetes, ⁷⁴hypertension, use of drugs that treat opportunistic infections, and toxicity due to anti-retroviral therapy ⁷⁵(ART) from tenofovir disoproxil fumarate (TDF) and indinavir (6, 8-11). Further, YPLHIV in SSA are 76 particularly vulnerable to developing CKD compared to adults living with HIV due to late HIV diagnosis 77 and initiation on ART, poorer adherence to ART complicated by high viremia and low CD4 cell counts $78(12-14)$.

⁷⁹CKD is associated with high morbidity and mortality as diagnosis is usually delayed, often occurring after

80 kidney failure due to its insidious onset (15). Kidney failure can only be treated with expensive kidney

81 replacement therapies that are not readily available in low and middle-income countries (16). Early

82 diagnosis is important to minimise risk of progression to kidney failure and cardiovascular events (17).

83 Diagnosis of CKD is based on the level of glomerular filtration rate (GFR) and markers of kidney damage

84 such as protein excretion into the urine shown by proteinuria or albuminuria (18). GFR can either be

85 measured directly (mGFR) or estimated (eGFR) with a specific biomarker and one of the estimating

86 equations (19). Most commonly, serum creatinine and cystatin C estimating equations are used to

87 estimate GFR (18, 20). Serum creatinine is widely available and relatively cheap (21) but has limitations

88 as it is influenced by muscle mass, physical activity and general health status (22) as well as high analytic

89 variability (21). Cystatin C is not affected by these conditions as it is produced by most nucleated cells

90 and has uniform generation despite individual differences in people and situations (22-24). However, it is

91 affected by conditions of high inflammation, corticosteroid use and thyroid disease (25). Cystatin C more

92 accurately estimated measured GFR compared to creatinine (26) in a large cohort study done across

⁹³Uganda, Malawi and South Africa that recommended the use of Cystatin C in African populations (4).

⁹⁴Although YPLHIV are at high risk of CKD, little is known about CKD prevalence, the best biomarker to 95 diagnose CKD and factors associated with CKD in this vulnerable group. Therefore, we sought to study 96 this among YPLHIV in Kampala, Uganda.

⁹⁷**Methods**

⁹⁸**Study design and setting:** This cross-sectional study was conducted in the HIV clinics of seven urban 99 public health facilities from the $12th$ of April 2023 to 31st January 2024 in Kampala, Uganda. These offer 100 comprehensive HIV care to children (aged below 18 years) and adults (aged 18 years and above). ¹⁰¹**Study population and sampling:** The study included YPLHIV aged 10-24 years with presumed perinatal 102 HIV infection (defined as being diagnosed with HIV before 10 years of age with self-report of no sexual 103 debut or blood transfusion prior to diagnosis). Pregnant YPLHIV were excluded. Systematic random 104 sampling was used to identify potential participants from all YPLHIV enrolled in the seven HIV clinics 105 from electronic medical records. They were ordered by age at diagnosis and every third person invited to 106 join the study. A sample size of 500 was powered to detect a prevalence of CKD between 16% and 24%. ¹⁰⁷**Study procedures:** Eligible participants were invited to the HIV clinic through a phone call where they 108 were screened, consented, and enrolled. A trained study team member conducted an interview with the 109 participant and completed a questionnaire to record demographic information, symptoms, risk factors and 110 the relevant medical history. Anthropometric measurements (mid-upper arm circumference (MUAC), ¹¹¹weight and height) were taken. Weight was assessed using a digital weighing scale, height using a 112 stadiometer and blood pressure (BP) using a digital BP machine with a paediatric cuff for younger 113 participants. Body composition monitoring was conducted using bioimpedance impedance spectroscopy ¹¹⁴(BIS) to measure body fat, muscle mass and visceral fat. Participants provided a spot urine sample (20 115 mls) as well as 8 ml of venous blood. Urine dipstick was done at the facility to determine proteinuria and

116 other urinary abnormalities. The samples were stored in a cooler box before transfer to the study

117 laboratory on the same day.

¹¹⁸**Laboratory methods and testing:** In the laboratory, serum creatinine, urinary albumin and cystatin C 119 levels were determined. Those with an albumin creatinine ratio $(ACR) >30$ mg/g or eGFR $120 \leq 60$ ml/min/1.73m² at baseline were followed-up after three months to confirm the KDIGO guideline-121 recommended clinical diagnosis of CKD. Cystatin C was measured by particle-enhanced 122 immunoturbidimetric assay on Roche Cobas C311 platform with Tina-quant Cystatin C Gen.2. Creatinine 123 was measured using the enzymatic calorimetric method using an isotope dilution mass spectroscopy ¹²⁴(IDMS) traceable standard reference material on the Cobas Integra 400 plus machine with Creatinine Plus 125 Version 2 (CREP2), Roche Diagnostics. The urine albumin was quantified using the 126 immunoturbidimetric assay on the Roche Cobas C311 platform using Tina \Box quant Albumin Gen2, (Roche 127 Diagnostics). Prior to testing, the machines were calibrated according to manufacturer instructions. 128 Urinalysis by dipstick was done with AYDMED urinalysis Reagent Test Strips (Sungo Europe B.V 129 Amsterdam) to determine presence of urobilinogen, bilirubin, ketones, blood, proteins, nitrites, 130 leucocytes, glucose, specific gravity, pH, and ascorbic acid (27). ¹³¹**Diagnosis of CKD** was based on the kidney disease improving global outcomes (KDIGO) guidelines 132 (28), i.e. 1) markers of kidney damage such as an albumin: creatinine ratio >30 mg/g, or 2) eGFR 133 ≤ 60 ml/min/1.73m², with these abnormalities confirmed with a repeat test after three months (29). To ¹³⁴explore CKD definition in this cohort that included children and where chronic disease had affected 135 pubertal development and mean body and muscle mass, we primarily used a range of GFR estimating 136 equations and eGFR cut offs that reflected contemporary practice for adults and children and/or sought to 137 adjust for body size. eGFRscr was estimated using the following creatinine-based equations: CKD ¹³⁸Epidemiology collaboration (CKDEPI) 2021 (30), the Bedside Schwartz (31), and Cockroft-Gault. 139 eGFRcystc was estimated using the following cystatin C-based equations: Schwartz cystatin C (32) and ¹⁴⁰CKDEPI 2012 (33). For completeness prevalence was also estimated using other relevant equations (Full 141 Age Spectrum, CKDEPI40 and Pierce U25), and in combination with ACR and proteinuria. Since a

142 normal GFR is between 90-120 ml/min/1.73m², we also considered a eGFR cut off below

143 90ml/min/1.73m² which is considered stage 2 CKD as abnormal in such a young population (34).

¹⁴⁴**Data management and statistical analysis**: Data were collected in REDCap and analysed with STATA 145 statistical software version 18 (STATA Corp USA). Viral suppression was considered as an HIV viral 146 load below 1000 copies/ml. Hypertension was classified according to the AAP guidelines as being above the 95th percentile for age and sex below 13 years and above 130/80 in those above 13 years (35). Muscle 148 mass was abnormal if below 33.3 for males and 24.3 for females. Social economic status was divided into 149 three using principal component analysis. Demographic data were summarised in percentages or means 150 (standard deviation) and median (interquartile range). The distribution of eGFRs estimated with different 151 equations was shown in a Kernel density plot. CKD prevalence diagnosed by either creatinine or cystatin ¹⁵²C was calculated. Univariable logistic regression was used to estimate odds ratios (OR) of factors 153 associated with CKD for each of the five equations used, respectively. All variables with p<0.2 in the ¹⁵⁴univariable model, and a-priori identified variables known to be associated with CKD (age, sex, HIV viral 155 suppression, blood pressure) were then included in a multivariable logistic regression model for each of 156 the five equations.

¹⁵⁷**Ethical considerations**

¹⁵⁸Ethical approval was received from the Uganda Virus Research Institute (UVRI) Research Ethics 159 Committee (reference number GC/127/946), the Uganda National Council of Science and Technology ¹⁶⁰(HS2578ES) and the London School of Hygiene and Tropical Medicine institutional review board ¹⁶¹(28797). Information about the study appropriate for adults, semi-literate adults and children was ¹⁶²provided in an information booklet that was read to the participants and caregivers. All the participants 163 more than 18 years of age provided a written informed consent. Those below 18 years of age provided 164 assent and their caregivers provided written informed consent. If a child refused to provide assent even 165 after their caregiver had provided consent, that child was not enrolled into the study. All participants had 166 the option to withdraw at any point during the research. All participants with suspected CKD were 167 referred to a nephrologist for management.

¹⁶⁸**Results**

- ¹⁶⁹Of 532 YPLHIV invited to participate, 500 were enrolled as the 32 declined to participate (**Table 1**). The
- 170 majority were female (56.0%; n=280), children aged 10-17 years (66.9%; n=335) and living in Kampala
- ¹⁷¹(58.9%; n=295). Females had better nutritional indicators than males they were less likely to be
- 172 underweight (26.4% vs 48.9%; p<0.001), not stunted (85.6% vs 76.9%; p=0.03), and to have normal mid
- 173 upper circumference $(92.9\% \text{ vs } 87.7\%; \text{p=0.05}).$

¹⁷⁴**Table 1: Demographic characteristics of the study participants by sex.**

Abnormal muscle mass 35 (16.0) 33 (12.3) 69 (14.7)
^{*} Living outside Kampala/Wakiso region. # included those with no religion and those of African traditional religion.

¹⁷⁶***Only those aged less than 19 years. 1 one missing, 2. 32 missing as their measurements were below threshold of*

 the BIS machine.

¹⁷⁸**Comparison of serum creatinine and cystatin C**

179 The mean serum creatinine (scr) was 0.63 mg/d (SD 0.15) with a range of 0.29 to 1.2mg/dl. The mean scr

180 was significantly different according to sex, age, presence of stunting or viral suppression. The mean

181 cystatin C was 0.81 mg/dl (SD 0.13) with a range of 0.51 to 1.39 mg/dl. The mean cystatin C was higher

182 in males at 0.86 mg/dl versus 0.78 mg/dl in females but with no other differences (**Supplemental table**

¹⁸³**1**). Serum creatinine but not cystatin C was correlated with age and sex (**Figure 1**).

¹⁸⁴**Figure 1: Relationship between serum creatinine and cystatin C and age for males and females**

¹⁸⁶**Distribution of the eGFR**

185

- 187 CKDEPI consistently gave higher eGFR readings for both creatinine and cystatin C, and the Schwartz
- 188 cystatin C equation gave the lowest eGFR values (**Figure 2**).

189 Figure 2. Kernel density plot showing the distribution of the eGFR according to different estimating

190 equations and biomarkers.

¹⁹²*Scr serum creatinine, CG cockroft Gault, cys Cystatin C*

¹⁹³**Prevalence of CKD using eGFR**

- ¹⁹⁴CKD prevalence varied according to the eGFR cut-off, and the biomarker used. Using an
- 195 eGFR<60ml/min/1.73m² cut-off, the highest prevalence was with the Schwartz cystatin C equation
- ¹⁹⁶(1.4%; 95% CI: 0.5-2.9% at baseline; 0.8%; 95% CI: 0.2-2.1% at 3-month follow-up) and the lowest with
- 197 the CKDEPI 2021 equation $(0\%; 95\% \text{ CI } 0.07\%)$. Similarly, using eGFR< $90 \text{ml/min}/1.73 \text{m}^2$ cut-off,
- 198 the highest prevalence was with the Schwartz cystatin C equation (58.9%; 95% CI: 54.4-63.3%) and the
- 199 lowest with CKDEPI (0.6%; 95% CI: 0.01-1.7%) (**Figure 3**). Prevalence using other eGFR equations
- 200 ranged from 0% to 27.5% (**Supplementary Table 2**).
- ²⁰¹**Figure 3 Prevalence of CKD according to the different estimating equations and biomarkers.**

It is made available under a CC-BY-NC 4.0 International license. **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2024.09.02.24312932;](https://doi.org/10.1101/2024.09.02.24312932) this version posted September 3, 2024. The copyright holder for this preprint

²⁰³**Prevalence of CKD according to eGFR and ACR**

204 All participants were staged according to combined baseline eGFR using cystatin C and ACR to assess

- ²⁰⁵risk of progression (28). Overall, 438 (88.5%) participants had low risk of progression (green), 53
- ²⁰⁶(10.7%) had intermediate risk of progression (yellow) and 4 (0.8%) were at high risk of progression
- ²⁰⁷(orange) (**Table 2**).

²⁰⁸**Table 2. All participants' CKD status staged according to estimated GFR from cystatin C and** albumin creatinine ratio at baseline.

210 eGFR estimated glomerular filtration rate, ACR Albumin creatinine ratio, *6 participants were missing

211 serum creatinine and cystatin C results.

²¹²**Prevalence of CKD according to markers of kidney damage**

- 213 Urinalysis showed that 143 (29%) participants had proteinuria on dipstick. Prevalence of proteinuria was
- 214 similar for those with eGFR>90ml/min/1.73m² and <90ml/min/1.73m² (24.6% vs 31.7% p=0.17). At
- 215 baseline, 10.1% (50) and at follow up, 3.8% (19) participants had an ACR >30 mg/g.

²¹⁶**Factors associated with CKD.**

- 217 Factors associated with CKD varied with the equation and biomarker used for those with an eGFR
- 218 ≤ 90 ml/min/1.73m² (Table 3) but was largely associated with male sex (with the exception of
- 219 CKDEPI2021), viral non-suppression (by the cystatin C based equations), increasing age (by the CKDEPI
- 220 and Bedside Schwartz equations), and being overweight (with the exception of the Cockroft-Gault
- 221 equation). CKD was also associated with proteinuria (by the CKDEPI 2012 equation) and being on a
- ²²²TDF-based regimen (by the Bedside Schwartz equation). There was no evidence that CKD was associated
- 223 with high blood pressure, muscle mass, and ACR.
- 224 Results were similar when using CKD defined by eGFR<60ml/min/1.73m² (**Supplementary Table 3**).
- Table 3. Factors associated with having CKD (eGFR<90**ml/min/1.73m2** ²²⁵) among study participants
- 226 according to the different estimating equations and biomarkers.
- ²²⁷*OR Odds ratio ART Anti-retroviral therapy. N Number, eGFR estimated glomerular filtration rate**
- ²²⁸*Adjusted for age, sex, blood pressure, viral suppression proteinuria, baseline CD4 T cell count.*

²²⁹**Discussion**

230 This is the first study to compare the prevalence and factors associated with CKD diagnosed by creatinine

- 231 and cystatin C among YPLHIV in Uganda according to standard guidelines. We found highly variable
- ²³²prevalence depending on the definition, the estimating equation and the biomarker used. This was

233 compounded by the commonly used GFR estimating equations being recommended for adults or children 234 only, despite the highly variable physical and sexual maturity within this important age group where long-235 term disease management is critical. Using cystatin C eGFR measures consistently gave substantially 236 higher prevalence of CKD: using the Schwartz cystatin equation approximately 60% of YPLHIV had 237 eGFR <90mls/min/1.73m². While dipstick proteinuria is anticipated in this population largely treated with 238 anti-retroviral drugs, 10% of participants had substantially elevated levels of albuminuria. However, when 239 participants with baseline abnormalities were remeasured at 3 months according to the gold-standard 240 definition, overall prevalence of CKD was much lower. 241 The highest prevalence (59%) using an eGFR cutoff $\langle 90 \text{ml/min}/1.73 \text{m}^2$ at baseline which fell to 23% at

242 three months follow-up, was very high. This is similar to a study done in 96 Nigerian YPLHIV aged 15 to 243 29 years which found 53.3% prevalence (36) and a Tanzanian study among 240 YPLHIV aged less than 244 14 years that showed a prevalence of 28% (37). When kidney function was determined by eGFR below 245 60 ml/min/1.73m² on two separate occasions at least three months apart, the prevalence of CKD was 246 0.8%. This is lower than in a study done in Zambia among children living with HIV aged 1 to 18 years 247 that found a prevalence of 3.8% after 3 months (38). However, the children in this study were younger 248 than in this study.

249 Using a eGFR cut off of less than 60 ml/min/1.73m² excludes a large proportion of YPLHIV who are 250 already showing signs of impaired kidney function such as an ACR above $30mg/g$, proteinuria and 251 hypertension, and who would benefit from early intervention to halt progression of their kidney disease ²⁵²(39). Pottel et al. have shown that clinical manifestations of decreased kidney function in young people 253 start at GFR less than 75 ml/min/1.73m²; they recommend that the CKD definition should be revised to 254 reflect this (40) .

255 KDIGO recommends that screening and surveillance for CKD be tailored to the specific high risk group 256 (41). Our study suggests that using sequential estimation of eGFR over three months excludes YPLHIV at 257 risk of CKD, and might be misleading to the public health response whose goal is to halt progression and

258 to predict those who are in danger of kidney failure or development of cardiovascular complications (41). ²⁵⁹KDIGO further recommends that screening frequency should be based on the risk profile of the individual 260 and potential to progress (42). YPLHIV have the potential to progress due to the continued insult to the 261 kidney, one abnormal eGFR measurement that shows reduced kidney function should be sufficient for 262 them to be followed up regularly and managed.

²⁶³Estimating GFR in this population was challenging as the different estimating equations and biomarkers 264 gave very different results. This was worse as one transitioned from equations meant for those below 18 265 years to those equations meant for adults above 18 years. The difference in the eGFR was wide even in 266 the same individual. It is difficult to determine the true estimate for CKD among YPLHIV using these 267 estimating equations yet knowing the true estimate is important to plan the public health response for 268 CKD (15). Clinicians who seek to diagnose CKD and plan management may get confused about the true ²⁶⁹CKD status of an individual. Misdiagnosis and classification of YPLHIV removes the opportunity to 270 intervene early to halt progression to kidney failure (43). However, it is not surprising that each of the 271 estimating equations gave a different prevalence since each estimating equation reflects the characteristics 272 of the population/dataset that was used to develop it (44). There is an urgent need to develop estimating 273 equations for Africans living in Africa.

274 The use of GFR alone doesn't predict progression or mortality risk and other markers of kidney damage 275 such as albuminuria or proteinuria are used $(13, 45)$. When ACR was used, the prevalence was 10.1%. 276 This is lower than that reported among a Tanzanian cohort of YPLHIV aged 1 to 14 years which found a 277 prevalence of 20.1% (37). However, the ACR was determined at a single time point and included younger 278 children. Proteinuria prevalence was 29% which was high in such a young population. Proteinuria is an 279 early marker of HIV associated nephropathy (46) and if persistent, is predictive of CKD status in children 280 (47). However, we measured proteinuria only at baseline and yet two positive out of three readings are 281 used to diagnose persistent proteinuria (41).

282 Cystatin C emerged as a better biomarker than serum creatinine as eGFR calculated from Cystatin C was 283 above CKD stage 1 more consistently for all those that had an increased ACR, proteinuria or hypertension 284 which are markers of abnormal kidney function (18). Cystatin C was recommended by a recent study in 285 three countries (Uganda, Malawi, and South Africa) as the better biomarker in Africans (4). Cystatin C 286 should be recommended for the diagnosis of CKD in YPLHIV as well. 287 We found that age, sex, and HIV viral non-suppression were associated with CKD and that proteinuria, ²⁸⁸CD4 cell count, blood pressure, and being on a TDF regimen were not associated. A study among 289 perinatally infected YPLHIV in South Africa with a mean age of 12.0 years found sex, but not age or 290 blood pressure were associated with CKD (48). Males were also found to have more CKD than females in 291 a study in Zimbabwe (49). TDF use was also not associated with CKD status in a cohort of American

292 children with CKD (50) .

293

294 One of the strengths of this study is that we estimated the eGFR at two different time points more than 295 three months apart as recommended by KDIGO and were able to ascertain those that actually had CKD 296 according to the standard definition of CKD. However, most of the GFR estimating equations and normal 297 serum creatinine have not been validated in YPLHIV in resource-limited settings especially in Africa and 298 this makes it that much harder to determine the abnormal values in YPLHIV (4, 51). This could explain 299 the low correlation between eGFR and the markers of kidney damage found in this study. We determined 300 both markers of kidney damage (albuminuria and proteinuria) and function and could tell YPLHIV that 301 were at risk of CKD progression. The biggest limitation is that we did not measure the GFR using either 302 ioxehol or the nuclear tracers $99mTc$ -diethylenetriaminepentaacetic acid (DTPA) or ⁵¹Cr-EDTA (10) and 303 so we are unable to tell how accurate the eGFR was.

³⁰⁴**Conclusion**

³⁰⁵CKD prevalence among YPLHIV in Uganda varies widely depending on the biomarker and definition 306 used. However, there is a substantial prevalence of albuminuria and reduced eGFR suggesting HIV

- 307 programs should prioritize screening for CKD among YPLHIV. The definition of CKD and best
- 308 biomarker to use in YPLHIV should be further investigated to optimise detection of those with early
- 309 abnormalities of kidney function. Estimating equations should be validated against measured GFR in
- 310 young people to define how best to estimate GFR across older children and young adults in Africa.

³¹¹**List of abbreviations**

- EKFC European Kidney Function Consortium
- FAS Full Age Spectrum
- GFR Glomerular Filtration Rate
- HB Haemoglobin
- HIV Human Immunodeficiency Virus
- HIVAN HIV associated Nephropathy
- HIVICK HIV Immune Complex Kidney Disease
- HW Health Worker
- IQR Interquartile Range
- KDIGO Kidney Disease Improving Global Outcomes
- KRT Kidney replacement therapy
- MDRD Modification of Diet in Renal Disease
- MOH Ministry of Health
- NCD's Non-Communicable Diseases
- PCR Protein Creatinine Ratio
- PLHIV People Living with HIV AIDS
- RAAS Renin Angiotensin Aldosterone Systems
- RCT Randomised Controlled Trials
- SSA Sub Saharan Africa

312

³¹³**Declarations**

³¹⁴**Ethics approval and consent to participate**

315 Ethical approval was received from the Uganda Virus Research Institute (UVRI) Research Ethics

316 Committee (reference number GC/127/946), the Uganda National Council of Science and Technology

³¹⁷(HS2578ES) and the London School of Hygiene and Tropical Medicine institutional review board

³¹⁸(28797). Information about the study appropriate for adults, semi-literate adults and children was

319 provided in an information booklet that was read to the participants and caregivers. All the participants

320 more than 18 years of age provided a written informed consent. Those below 18 years of age provided

321 assent and their caregivers provided written informed consent. If a child refused to provide assent even

322 after their caregiver had provided consent, that child was not enrolled into the study. All participants had

323 the option to withdraw at any point during the research. All participants with suspected CKD were

324 referred to a nephrologist for management.

³²⁵**Consent for publication:** Not applicable

³²⁶**Availability of data and materials**

327 The data supporting the findings of this study are openly available in repository

³²⁸https://datacompass.lshtm.ac.uk/.

³²⁹**Competing interests**

330 The authors declare no conflict of interest.

³³¹**Funding**

³³²Support for research was provided by Fogarty International Centre, National Institutes of Health (grant

³³³#2D43TW009771-06) HIV and co-infections in Uganda. HAW is funded by the UK Medical Research

³³⁴Council (MRC) and the UK Department for International Development (DFID) under the MRC/DFID

³³⁵Concordat agreement (Grant 1: MR/R010161/1). EN, Doctoral Research Fellow, NIHR131273 is funded

336 by the NIHR for this research project. The views expressed in this publication are those of the authors and

337 not necessarily those of the NIHR, NHS or the UK Department of Health and Social Care.

³³⁸**Authors' contributions**

³³⁹EN, LT, RK, CDC, DN, BC, YCM, HW contributed to the conceptualization and design of the study, data

340 collection, analysis, and interpretation. EN, LT, YK drafted the manuscript. CDC, BC, RK, YCM edited

341 the draft manuscript. HW was responsible for the overall supervision of this work. All authors reviewed

342 and approved the manuscript before submission for publication.

³⁴³**Acknowledgements**

³⁴⁴The authors acknowledge the health workers and peers at the implementing facilities where this data was 345 collected. The HIV program at the participating health facilities is supported by the President's 346 Emergency Plan for AIDS Relief (PEPFAR) through CDC.

347

348

³⁴⁹**References**

350 1. Kovesdy CP. Epidemiology of chronic kidney disease: an update 2022. Kidney International Supplements. 2022;12(1):7-11. Supplements. 2022;12(1):7-11.

³⁵²2. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease:

It is made available under a CC-BY-NC 4.0 International license. **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2024.09.02.24312932;](https://doi.org/10.1101/2024.09.02.24312932) this version posted September 3, 2024. The copyright holder for this preprint

³⁵³Evaluation, classification, and stratification. American Journal of Kidney Disease 39:S1–S266. 2002.

354 3. Bikbov B, Purcell CA, Levey AS, Smith M, Abdoli A, Abebe M, et al. Global, regional, and
355 national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of 355 national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. The lancet. 2020:395(10225):709-33. Disease Study 2017. The lancet. 2020;395(10225):709-33.

357 4. Fabian J, Kalyesubula R, Mkandawire J, Hansen CH, Nitsch D, Musenge E, et al. Measurement
358 of kidney function in Malawi, South Africa, and Uganda: a multicentre cohort study. The Lancet Global 358 of kidney function in Malawi, South Africa, and Uganda: a multicentre cohort study. The Lancet Global
359 Health. 2022;10(8):e1159-e69. Health. 2022;10(8):e1159-e69.

360 5. Fabian J, George JA, Etheredge HR, van Deventer M, Kalyesubula R, Wade AN, et al. Methods
361 and reporting of kidney function: a systematic review of studies from sub-Saharan Africa. Clinical 361 and reporting of kidney function: a systematic review of studies from sub-Saharan Africa. Clinical
362 Kidney Journal. 2019;12(6):778-87. Kidney Journal. 2019;12(6):778-87.

³⁶³6. Naicker S, Fabian J. Risk factors for the development of chronic kidney disease with HIV/AIDS. Clin Nephrol. 2010;74 Suppl 1:S51-6.

365 7. Frigati LJ, Ameyan W, Cotton MF, Gregson CL, Hoare J, Jao J, et al. Chronic comorbidities in children and adolescents with perinatally acquired HIV infection in sub-Saharan Africa in the era of 366 children and adolescents with perinatally acquired HIV infection in sub-Saharan Africa in the era of antiretroviral therapy. The Lancet Child & Adolescent Health. 2020;4(9):688-98. ³⁶⁷antiretroviral therapy. The Lancet Child & Adolescent Health. 2020;4(9):688-98.

368 8. Jotwani V, Atta MG, Estrella MM. Kidney Disease in HIV: Moving beyond HIV-Associated Nephropathy. Journal of the American Society of Nephrology. 2017;28(11):3142-54. ³⁶⁹Nephropathy. Journal of the American Society of Nephrology. 2017;28(11):3142-54.

370 9. Kalyesubula R, Wearne N, Semitala FC, Bowa K. HIV-associated renal and genitourinary
371 comorbidities in Africa. Journal of acquired immune deficiency syndromes (1999). 2014;67 Suppl comorbidities in Africa. Journal of acquired immune deficiency syndromes (1999). 2014;67 Suppl 1:S68-78. 372

373 10. Purswani MU, Chernoff MC, Mitchell CD, Seage GR, Zilleruelo G, Abitbol C, et al. Chronic
374 kidney disease associated with perinatal HIV infection in children and adolescents. Pediatric nephrolog 374 kidney disease associated with perinatal HIV infection in children and adolescents. Pediatric nephrology.
375 2012;27(6):981-9. ³⁷⁵2012;27(6):981-9.

376 11. Bhimma R, Purswani MU, Kala U. Kidney disease in children and adolescents with perinatal HIV□1 infection. Journal of the International AIDS Society. 2013;16(1):18596. HIV^[1] infection. Journal of the International AIDS Society. 2013;16(1):18596.

378 12. Innes S, Patel K. Non-communicable diseases in adolescents with perinatally-acquired HIV-1 infection in high-and low-income settings. Current opinion in HIV and AIDS. 2018;13(3):187. infection in high-and low-income settings. Current opinion in HIV and AIDS. 2018;13(3):187.

380 13. Bunupuradah T, Phupitakphol T, Sophonphan J, Prasitsuebsai W, Anugulruengkitt S, 381 Jantarabenjakul W, et al. Prevalence of persistent renal dysfunction in perinatally HIV-infected

381 Jantarabenjakul W, et al. Prevalence of persistent renal dysfunction in perinatally HIV-infected Thai
382 adolescents. Pediatr Infect Dis J. 2018;37(1):66-70. adolescents. Pediatr Infect Dis J. 2018;37(1):66-70.

383 14. Bernheimer JM, Patten G, Makeleni T, Mantangana N, Dumile N, Goemaere E, et al. Paediatric HIV treatment failure: a silent epidemic. J Int AIDS Soc. 2015;18:20090. ³⁸⁴HIV treatment failure: a silent epidemic. J Int AIDS Soc. 2015;18:20090.

385 15. Stanifer JW, Muiru A, Jafar TH, Patel UD. Chronic kidney disease in low-and middle-income countries. Nephrology Dialysis Transplantation. 2016;31(6):868-74. countries. Nephrology Dialysis Transplantation. 2016;31(6):868-74.

387 16. Kalyesubula R, Makanga G, Gyagenda JO, Atuhe D, Kansiime G, Kiggundu D, et al. Nephrology
388 in Uganda. Nephrology Worldwide. 2021:75-83. in Uganda. Nephrology Worldwide. 2021:75-83.

It is made available under a CC-BY-NC 4.0 International license. **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2024.09.02.24312932;](https://doi.org/10.1101/2024.09.02.24312932) this version posted September 3, 2024. The copyright holder for this preprint

389 17. George C, Mogueo A, Okpechi I, Echouffo-Tcheugui JB, Kengne AP. Chronic kidney disease in
390 low-income to middle-income countries: the case for increased screening. BMJ Glob Health. 390 low-income to middle-income countries: the case for increased screening. BMJ Glob Health.
391 2017;2(2):e000256. 2017;2(2):e000256.

- 392 18. Lopez-Giacoman S, Madero M. Biomarkers in chronic kidney disease, from kidney function to
393 kidney damage. World journal of nephrology. 2015:4(1):57. kidney damage. World journal of nephrology. $2015;4(1):57$.
- 394 19. Levey AS, Titan SM, Powe NR, Coresh J, Inker LA. Kidney Disease, Race, and GFR Estimation.
395 Clinical Journal of the American Society of Nephrology. 2020;15(8):1203-12. ³⁹⁵Clinical Journal of the American Society of Nephrology. 2020;15(8):1203-12.
- 396 20. Carrara F, Gaspari F. GFR measured by iohexol: the best choice from a laboratory perspective.
397 Journal of Laboratory and Precision Medicine. 2018;3. Journal of Laboratory and Precision Medicine. 2018;3.
- 398 21. Kashani K, Rosner MH, Ostermann M. Creatinine: From physiology to clinical application.
399 European Journal of Internal Medicine. 2020;72:9-14. European Journal of Internal Medicine. 2020;72:9-14.
- 400 22. Shlipak MG, Mattes MD, Peralta CA. Update on cystatin C: incorporation into clinical practice.
401 American Journal of Kidney Diseases. 2013;62(3):595-603. American Journal of Kidney Diseases. 2013;62(3):595-603.

402 23. Seape T, Gounden V, van Deventer HE, Candy GP, George JA. Cystatin C- and creatinine-based
403 equations in the assessment of renal function in HIV-positive patients prior to commencing Highly Active 403 equations in the assessment of renal function in HIV-positive patients prior to commencing Highly Active
404 Antiretroviral Therapy. Annals of Clinical Biochemistry. 2016;53(1):58-66. Antiretroviral Therapy. Annals of Clinical Biochemistry. 2016;53(1):58-66.

24. Mauss S, Berger F, Kuschak D, Henke J, Hegener P, Wolf E, et al. Cystatin C as a marker of renal function is affected by HIV replication leading to an underestimation of kidney function in HIV 406 renal function is affected by HIV replication leading to an underestimation of kidney function in HIV patients. SAGE Publications Sage UK: London, England; 2008. patients. SAGE Publications Sage UK: London, England; 2008.

408 25. Mian AN, Schwartz GJ. Measurement and estimation of glomerular filtration rate in children.
409 Advances in chronic kidney disease. 2017;24(6):348-56. Advances in chronic kidney disease. 2017;24(6):348-56.

410 26. Shlipak MG, Matsushita K, Ärnlöv J, Inker LA, Katz R, Polkinghorne KR, et al. Cystatin C
411 versus creatinine in determining risk based on kidney function. New England Journal of Medicine. 411 versus creatinine in determining risk based on kidney function. New England Journal of Medicine.
412 2013;369(10):932-43. ⁴¹²2013;369(10):932-43.

⁴¹³27. Queremel Milani DA, Jialal I. Urinalysis: StatPearls Publishing, Treasure Island (FL); 2020 2020.

414 28. Levin A, Stevens PE, Bilous RW, Coresh J, De Francisco AL, De Jong PE, et al. Kidney Disease:
415 Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for 415 Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney international supplements. 416 the evaluation and management of chronic kidney disease. Kidney international supplements.
417 2013;3(1):1-150. $2013;3(1):1-150.$

- 418 29. Levey AS, Eckardt K-U, Dorman NM, Christiansen SL, Cheung M, Jadoul M, et al.
419 Nomenclature for kidney function and disease: executive summary and glossary from a Kidn
- 419 Nomenclature for kidney function and disease: executive summary and glossary from a Kidney Disease: 420 Improving Global Outcomes (KDIGO) consensus conference. Kidney Diseases. 2020;6(5):309-17.
- Improving Global Outcomes (KDIGO) consensus conference. Kidney Diseases. 2020;6(5):309-17.
- 421 30. Inker LA, Eneanya ND, Coresh J, Tighiouart H, Wang D, Sang Y, et al. New Creatinine- and
422 Cystatin C–Based Equations to Estimate GFR without Race. New England Journal of Medicine.
- 422 Cystatin C–Based Equations to Estimate GFR without Race. New England Journal of Medicine.
423 2021:385(19):1737-49.
- ⁴²³2021;385(19):1737-49.

424 31. Schwartz GJ, Munoz A, Schneider MF, Mak RH, Kaskel F, Warady BA, et al. New equations to estimate GFR in children with CKD. Journal of the American Society of Nephrology: JASN. 425 estimate GFR in children with CKD. Journal of the American Society of Nephrology: JASN.
426 2009;20(3):629. ⁴²⁶2009;20(3):629.

427 32. Schwartz GJ, Schneider MF, Maier PS, Moxey-Mims M, Dharnidharka VR, Warady BA, et al.
428 Improved equations estimating GFR in children with chronic kidney disease using an 428 Improved equations estimating GFR in children with chronic kidney disease using an immunonephelometric determination of cystatin C. Kidney International. 2012;82(4):4 immunonephelometric determination of cystatin C. Kidney International. 2012;82(4):445-53.

430 33. Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene T, et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. New England Journal of Medicine. 431 glomerular filtration rate from serum creatinine and cystatin C. New England Journal of Medicine.
432 2012;367(1):20-9. ⁴³²2012;367(1):20-9.

⁴³³34. Levey AS, Coresh J. Chronic kidney disease. The Lancet. 2012;379(9811):165-80.

434 35. Flynn JT, Falkner BE. New Clinical Practice Guideline for the Management of High Blood
435 Pressure in Children and Adolescents. Hypertension (Dallas, Tex : 1979). 2017;70(4):683-6. ⁴³⁵Pressure in Children and Adolescents. Hypertension (Dallas, Tex : 1979). 2017;70(4):683-6.

436 36. Okafor UH, Unuigbe EI, Chukwuonye E. Prevalence and clinical and laboratory characteristics of kidney disease in anti-retroviral-naive human immunodeficiency virus-infected patients in South-South

437 kidney disease in anti-retroviral-naive human immunodeficiency virus-infected patients in South-South
438 Nigeria. Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Cente 438 Nigeria. Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center
439 for Organ Transplantation, Saudi Arabia. 2016;27(1):129-34. for Organ Transplantation, Saudi Arabia. 2016;27(1):129-34.

440 37. Fredrick F, Francis JM, Ruggajo PJ, Maro EE. Renal abnormalities among HIV infected children
441 at Muhimbili National Hospital (MNH)-Dar es Salaam, Tanzania. BMC nephrology. 2016;17:30. ⁴⁴¹at Muhimbili National Hospital (MNH)-Dar es Salaam, Tanzania. BMC nephrology. 2016;17:30.

442 38. Zimba KM. Prevalence and factors associated with renal dysfunction in HIV positive paediatric
443 detection bighly active antiretroviral therapy at the paediatric centre of excellence of the university 443 patients on highly active antiretroviral therapy at the paediatric centre of excellence of the university
444 teaching hospital, in Lusaka, Zambia. Pediatric Nephrology. 2016;31(10):1778. teaching hospital, in Lusaka, Zambia. Pediatric Nephrology. 2016;31(10):1778.

445 39. Uhlig K, Johnson CA, Levey AS. New guidelines spell out approach to chronic kidney disease:
446 early diagnosis of chronic kidney disease widens the window of opportunity to put effective treatments t 446 early diagnosis of chronic kidney disease widens the window of opportunity to put effective treatments to
447 work. Recent National Kidney Foundation clinical practice guidelines provide a simple definition, a

447 work. Recent National Kidney Foundation clinical practice guidelines provide a simple definition, a practical staging system, and a stage-appropriate action plan. Patient Care. 2003;37(7):38-45. ⁴⁴⁸practical staging system, and a stage-appropriate action plan. Patient Care. 2003;37(7):38-45.

449 40. Pottel H, Hoste L, Delanaye P. Abnormal glomerular filtration rate in children, adolescents and
450 voung adults starts below 75 mL/min/1.73 m 2. Pediatric Nephrology. 2015:30:821-8. ⁴⁵⁰young adults starts below 75 mL/min/1.73 m 2. Pediatric Nephrology. 2015;30:821-8.

451 41. Levey A, Atkins R, Coresh J, Cohen E, Collins A, Eckardt K-U, et al. Chronic kidney disease as
452 a global public health problem: approaches and initiatives–a position statement from Kidney Disease 452 a global public health problem: approaches and initiatives–a position statement from Kidney Disease
453 Improving Global Outcomes. Kidney international. 2007;72(3):247-59. Improving Global Outcomes. Kidney international. 2007;72(3):247-59.

454 42. Shlipak MG, Tummalapalli SL, Boulware LE, Grams ME, Ix JH, Jha V, et al. The case for early identification and intervention of chronic kidney disease: conclusions from a Kidney Disease: Improving 455 identification and intervention of chronic kidney disease: conclusions from a Kidney Disease: Improving
456 Global Outcomes (KDIGO) Controversies Conference. Kidney international. 2021;99(1):34-47. ⁴⁵⁶Global Outcomes (KDIGO) Controversies Conference. Kidney international. 2021;99(1):34-47.

457 43. Bhimma R. HIV-Related Kidney Diseases. In: Bobat R, editor. HIV Infection in Children and Adolescents. Cham: Springer International Publishing; 2020. p. 143-52. Adolescents. Cham: Springer International Publishing; 2020. p. 143-52.

459 44. Miller WG. Perspective on New Equations for Estimating Glomerular Filtration Rate. Clinical Chemistry. 2021;67(6):820-2. Chemistry. 2021;67(6):820-2.

It is made available under a CC-BY-NC 4.0 International license. **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2024.09.02.24312932;](https://doi.org/10.1101/2024.09.02.24312932) this version posted September 3, 2024. The copyright holder for this preprint

- ⁴⁶¹45. Bökenkamp A. Proteinuria—take a closer look! Pediatric Nephrology. 2020;35(4):533-41.
- 462 46. Palau L, Menez S, Rodriguez-Sanchez J, Novick T, Delsante M, McMahon BA, et al. HIV-
463 associated nephropathy: links, risks and management. HIV AIDS (Auckl). 2018;10:73-81. associated nephropathy: links, risks and management. HIV AIDS (Auckl). 2018;10:73-81.
- 464 47. Beng H, Rakhmanina N, Moudgil A, Tuchman S, Ahn S-Y, Griffith C, et al. HIV-associated CKDs in children and adolescents. Kidney international reports. 2020;5(12):2292-300. ⁴⁶⁵CKDs in children and adolescents. Kidney international reports. 2020;5(12):2292-300.
- 466 48. Frigati L, Mahtab S, Nourse P, Ray P, Perrazzo S, Machemedze T, et al. Prevalence of risk
467 factors for chronic kidney disease in South African youth with perinatally acquired HIV. Pediatric 467 factors for chronic kidney disease in South African youth with perinatally acquired HIV. Pediatric nephrology (Berlin, Germany). 2018;34(2):313-8. nephrology (Berlin, Germany). 2018;34(2):313-8.
- 469 49. Byers BW, Drak D, Shamu T, Chimbetete C, Dahwa R, Gracey DM. Assessing renal impairment
470 in treatment-naïve adolescents living with HIV commencing antiretroviral therapy in Zimbabwe. AIDS. 470 in treatment-naïve adolescents living with HIV commencing antiretroviral therapy in Zimbabwe. AIDS.
471 2023;37(5):789-94. ⁴⁷¹2023;37(5):789-94.
- 472 50. Purswani M, Patel K, Kopp JB, Seage GR, 3rd, Chernoff MC, Hazra R, et al. Tenofovir treatment
473 duration predicts proteinuria in a multiethnic United States Cohort of children and adolescents with
- 473 duration predicts proteinuria in a multiethnic United States Cohort of children and adolescents with
474 perinatal HIV-1 infection. Pediatr Infect Dis J. 2013;32(5):495-500.
- perinatal HIV-1 infection. Pediatr Infect Dis J. 2013;32(5):495-500.
- 475 51. Swanepoel CR, Atta MG, D'Agati VD, Estrella MM, Fogo AB, Naicker S, et al. Kidney disease
476 in the setting of HIV infection: conclusions from a Kidney Disease: Improving Global Outcomes
- 476 in the setting of HIV infection: conclusions from a Kidney Disease: Improving Global Outcomes
477 (KDIGO) Controversies Conference. Kidney international. 2018;93(3):545-59.
- ⁴⁷⁷(KDIGO) Controversies Conference. Kidney international. 2018;93(3):545-59.

